EGFR and non-small cell lung carcinoma: In several phase III studies, EGFR TKIs have shown favorable clinical efficacy as compared with platinum-based doublet chemotherapy as first‐line therapy in patients with advanced NSCLC with EGFR mutations, with improved Progression-Free Survival (PFS), response rate, quality of life and acceptable toxicity.13